부산대학교 도서관

Aim: Tau truncation (tr‐tau) by active caspase‐6 (aCasp‐6) generates tau fragments that may be toxic. Yet the relationship between aCasp‐6, different forms of tr‐tau and hyperphosphorylated tau (p‐tau) accumulation in human brains with Alzheimer's disease (AD) and other tauopathies remains unclear. Methods: We generated two neoepitope monoclonal antibodies against tr‐tau sites (D402 and D13) targeted by aCasp‐6. Then, we used five‐plex immunofluorescence to quantify the neuronal and astroglial burden of aCasp‐6, tr‐tau, p‐tau and their co‐occurrence in healthy controls, AD and primary tauopathies. Results: Casp‐6 activation was strongest in AD and Pick's disease (PiD) but almost absent in 4‐repeat (4R) tauopathies. In neurons, the tr‐tau burden was much more abundant in AD and PiD than in 4R tauopathies and disproportionally higher when normalising by p‐tau pathology. Tr‐tau astrogliopathy was detected in low numbers in 4R tauopathies. Unexpectedly, about half of tr‐tau positive neurons in AD and PiD lacked p‐tau aggregates, a finding we confirmed using several p‐tau antibodies. Conclusions: Early modulation of aCasp‐6 to reduce tr‐tau pathology is a promising therapeutic strategy for AD and PiD but is unlikely to benefit 4R tauopathies. The large percentage of tr‐tau‐positive neurons lacking p‐tau suggests that many vulnerable neurons to tau pathology go undetected when using conventional p‐tau antibodies. Therapeutic strategies against tr‐tau pathology could be necessary to modulate the extent of tau abnormalities in AD. The disproportionally higher burden of tr‐tau in AD and PiD supports the development of biofluid biomarkers against tr‐tau to detect AD and PiD and differentiate them from 4R tauopathies at a patient level. [ABSTRACT FROM AUTHOR]